The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea

Koo, Bon San; Hong, Seokchan; Kim, You Jae; Lee, Chang Keun; Yoo, Bin

doi:10.4078/jrd.2015.22.5.288

Cited by 3 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no direct RCTs related to the KCQs corresponding to this recommendation. Three observational studies and three meta-analyses showed that compared to fusion proteins (etanercept), monoclonal TNF inhibitors (infliximab and adalimumab) generally showed better outcomes in terms of the incidence or flare rates of uveitis or IBD [ 112 – 117 ]. Further, IL-17 inhibitors may exacerbate IBD in patients with axSpA [ 118 ].…”

Section: Recommendations For the Treatment Of Patients With Axial Spo...mentioning

confidence: 99%

“…In patients with active axSpA resistant to NSAID therapy who have uveitis or IBD, we suggest treatment with monoclonal TNF inhibitors as initial biological agents (GoE, low; SoR, weak; LoA 100%) There are no direct RCTs related to the KCQs corresponding to this recommendation. Three observational studies and three meta-analyses showed that compared to fusion proteins (etanercept), monoclonal TNF inhibitors (infliximab and adalimumab) generally showed better outcomes in terms of the incidence or flare rates of uveitis or IBD [112][113][114][115][116][117]. Further, IL-17 inhibitors may exacerbate IBD in patients with axSpA [118].…”

Section: Pharmacological Treatment In Active Diseasementioning

confidence: 99%

See 1 more Smart Citation

Korean treatment recommendations for patients with axial spondyloarthritis

Seo

Yeo

Park

et al. 2023

Korean J Intern Med

View full text Add to dashboard Cite

We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and Kmbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5–12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors. Recommendations 13–16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.

show abstract

Section: Recommendations For the Treatment Of Patients With Axial Spo...mentioning

confidence: 99%

Section: Pharmacological Treatment In Active Diseasementioning

confidence: 99%

Korean treatment recommendations for patients with axial spondyloarthritis

Seo

Yeo

Park

et al. 2023

Korean J Intern Med

View full text Add to dashboard Cite

show abstract

“…There are no direct RCTs related to the KCQs corresponding to this recommendation. Three observational studies and three meta-analyses showed that compared to fusion proteins (etanercept), monoclonal TNF inhibitors (infliximab and adalimumab) generally showed better outcomes in terms of the incidence or flare rates of uveitis or IBD [112][113][114][115][116][117]. Further, IL-17 inhibitors may exacerbate IBD in patients with axSpA [118].…”

Section: Recommendation 6 In Patients With Active Axspa Resistantmentioning

confidence: 99%

Korean treatment recommendations for patients with axial spondyloarthritis

et al. 2023

View full text Add to dashboard Cite

We aimed to develop evidence-based recommendations for treating axial spondylarthritis (axSpA) in Korea. The development committee was constructed, key clinical questions were determined, and the evidence was searched through online databases including MEDLINE, Embase, Cochrane, KoreaMed, and KMbase. Systematic literature reviews were conducted, quality of evidence was determined, and draft recommendations were formulated according to the Grading of Recommendations Assessment, Development, and Evaluations methodology. Recommendations that reached 80% consensus among a voting panel were finalized. Three principles and 21 recommendations were determined. Recommendations 1 and 2 pertain to treatment strategies, regular disease status assessment, and rheumatologist-steered multidisciplinary management. Recommendations 3 and 4 strongly recommend patient education, exercise, and smoking cessation. Recommendations 5~12 address pharmacological treatment of active disease using nonsteroidal anti-inflammatory drugs, glucocorticoids, sulfasalazine, biologics, and Janus kinase inhibitors. Recommendations 13~16 address treatment in stable disease. We suggest against spa and acupuncture as therapies (Recommendation 17). Recommendations 18 and 19 pertain to total hip arthroplasty and spinal surgery. Monitoring of comorbidities and drug toxicities are recommended (Recommendations 20 and 21). Recommendations for axSpA treatment in a Korean context were developed based on comprehensive clinical questions and evidence. These are intended to guide best practice in the treatment of axSpA.

show abstract

“…In a previous issue of this journal, Koo et al [8] demonstrated the relative incidence rate of uveitis, including the first episode while using TNF inhibitors and concluded there was no difference in the incidence rate of uveitis among the three TNF inhibitors. Eight years of follow up, analysis of survival using the Kaplan-Meier method and Cox proportional hazards model are the strong points of this study.…”

Section: The Incidence Of Uveitis In Ankylosing Spondylitis Patients mentioning

confidence: 99%